Onzemipgene Parvec

哌昂泽米基

Report date: 2025/11/11 17:42:31

Base Information

Drug NameOnzemipgene Parvec
Drug Alias NameHMR-59JNJ-81201887JNJ-1887AAVCAGsCD59
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionCD59 glycoprotein gene transference
TargetsCD59 glycoprotein
Therapy Area/IndicationsPyruvate kinase deficiencyGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTufts University
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen Research & Development LlcWuxi Kejin Biotechnology Co Ltd
Inactive CompaniesHemera Biosciences Inc
Active IndicationsPyruvate kinase deficiencyGeographic AtrophyMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A